234 related articles for article (PubMed ID: 27533459)
1. MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.
Zhong X; Xie G; Zhang Z; Wang Z; Wang Y; Wang Y; Qiu Y; Li L; Bu H; Li J; Zheng H
Oncotarget; 2016 Sep; 7(38):61166-61182. PubMed ID: 27533459
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
Hoppe R; Achinger-Kawecka J; Winter S; Fritz P; Lo WY; Schroth W; Brauch H
Eur J Cancer; 2013 Nov; 49(17):3598-608. PubMed ID: 23968733
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS6 suppresses tumor progression via the ERK signaling pathway and serves as a prognostic marker in human breast cancer.
Xie Y; Gou Q; Xie K; Wang Z; Wang Y; Zheng H
Oncotarget; 2016 Sep; 7(38):61273-61283. PubMed ID: 27542224
[TBL] [Abstract][Full Text] [Related]
4. PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
Fan Y; Xie G; Wang Z; Wang Y; Wang Y; Zheng H; Zhong X
Breast Cancer Res Treat; 2022 Feb; 192(1):33-42. PubMed ID: 34978016
[TBL] [Abstract][Full Text] [Related]
5. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
6. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines.
Ergun S; Tayeb TS; Arslan A; Temiz E; Arman K; Safdar M; Dağlı H; Korkmaz M; Nacarkahya G; Kırkbeş S; Oztuzcu S
Gene; 2015 Jan; 555(2):377-81. PubMed ID: 25447917
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F
Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
9. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
Zheng L; Meng X; Li X; Zhang Y; Li C; Xiang C; Xing Y; Xia Y; Xi T
FASEB J; 2018 Feb; 32(2):588-600. PubMed ID: 28939591
[TBL] [Abstract][Full Text] [Related]
10. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Ikeda K; Horie-Inoue K; Ueno T; Suzuki T; Sato W; Shigekawa T; Osaki A; Saeki T; Berezikov E; Mano H; Inoue S
Sci Rep; 2015 Aug; 5():13170. PubMed ID: 26255816
[TBL] [Abstract][Full Text] [Related]
11. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-409-3p regulates cell invasion and metastasis by targeting ZEB1 in breast cancer.
Ma Z; Li Y; Xu J; Ren Q; Yao J; Tian X
IUBMB Life; 2016 May; 68(5):394-402. PubMed ID: 27079864
[TBL] [Abstract][Full Text] [Related]
13. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics-based interaction analysis of miR-92a-3p and key genes in tamoxifen-resistant breast cancer cells.
Cun J; Yang Q
Biomed Pharmacother; 2018 Nov; 107():117-128. PubMed ID: 30086458
[TBL] [Abstract][Full Text] [Related]
15. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.
Chu X; Zhou Q; Xu Y; Jiang J; Li Q; Zhou Q; Wu Q; Jin M; Wang H; Gu Y; Wang X; Wang B; He S; He X; Wu C; Zhang F; Zhang Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):100. PubMed ID: 30795784
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression.
Xiao CZ; Wei W; Guo ZX; Zhang MY; Zhang YF; Wang JH; Shi M; Wang HY; Guo RP
J Cancer Res Clin Oncol; 2017 Feb; 143(2):263-273. PubMed ID: 27704267
[TBL] [Abstract][Full Text] [Related]
18. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
19. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
